​
​

Elevation Oncology Stock (NASDAQ:ELEV)

ForecastRevenueOwnershipFinancialsChart
Elevation Oncology by TradingView

Previous Close

$0.61

52W Range

$0.36 - $5.83

50D Avg

$1.64

200D Avg

$2.67

Market Cap

$35.98M

Avg Vol (3M)

$1.34M

Beta

1.27

Div Yield

-

ELEV Company Profile

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

29

IPO Date

Jun 25, 2021

Website

ELEV Performance

ELEV Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-45.45M$-94.55M$-32.05M
Net Income$-45.70M$-95.08M$-32.04M
EBITDA$-45.45M$-94.55M$-32.03M
Basic EPS-$-4.09$-2.64
Diluted EPS-$-4.09$-2.64

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
CWBRCohBar, Inc.
AVROAVROBIO, Inc.
OCEAOcean Biomedical, Inc.
HEPAHepion Pharmaceuticals, Inc.
ZURAZura Bio Limited
ENVBEnveric Biosciences, Inc.